World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
56853
World Ranking
8123
National Ranking
796

Peter Hillmen publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Peter Hillmen sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 630 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Peter Hillmen D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Peter Hillmen sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Peter Hillmen is affiliated with St James's University Hospital in the United Kingdom and has contributed extensively to the field of medicine, with a focus on hematology and related disorders. Their scholarly work spans several specialized subfields including genetics, pathology and forensic medicine, immunology, hematology, and pulmonary and respiratory medicine.

The scientist's research topics prominently include chronic lymphocytic leukemia, lymphoma diagnosis and treatment, the complement system in diseases, immunodeficiency and autoimmune disorders, chronic myeloid leukemia treatments, blood groups and transfusion, and advanced breast cancer therapies.

Peter Hillmen has published significant articles in a variety of academic journals. Notable recent papers include:

  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial, 2021, Journal of Clinical Oncology
  • Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2020, Annals of Oncology
  • Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia, 2022, New England Journal of Medicine
  • Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, 2021, New England Journal of Medicine
  • Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial, 2022, The Lancet Oncology

The venues where Peter Hillmen frequently publishes include Blood, Clinical Lymphoma Myeloma & Leukemia, British Journal of Haematology, Journal of Clinical Oncology, and Haematologica. These journals reflect their focus on hematological and oncological research.

Their collaborative network consists of several frequent co-authors, including:

  • Paolo Ghia
  • Jennifer R. Brown
  • Tadeusz Robak
  • Wojciech Jurczak
  • John C. Byrd

Hillmen's contributions have helped advance knowledge in chronic lymphocytic leukemia research, with many focused studies on therapeutic approaches and clinical outcomes in hematologic malignancies. Their work on the complement system has also addressed its role in various diseases, including paroxysmal nocturnal hemoglobinuria.

Best Publications

  • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

    Russell P. Rother;Leonard Bell;Peter Hillmen;Mark T. Gladwin

  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

    Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;Neal S. Young;Jörg Schubert;Robert A. Brodsky

  • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

    Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet

  • Natural history of paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;S.M. Lewis;Monica Bessler;Lucio Luzzatto

  • Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

    Charles Parker;Mitsuhiro Omine;Stephen Richards;Jun-Ichi Nishimura

  • Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Bonnie Harrington;Susan O'Brien;Jeffrey A. Jones

  • Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    John F. Seymour;Thomas J. Kipps;Barbara Eichhorst;Peter Hillmen

  • Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

    D Catovsky;S Richards;E Matutes;D Oscier

  • Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;Claire Hall;Judith C W Marsh;Modupe Elebute

  • Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

    William G. Wierda;Thomas J. Kipps;Jiří Mayer;Stephan Stilgenbauer

  • Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

    Andy C Rawstron;Fiona L Bennett;Sheila J M O'Connor;Marwan Kwok

  • Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

    Robert A. Brodsky;Neal S. Young;Elisabetta Antonioli;Antonio M. Risitano

  • Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

    Peter Hillmen;Aleksander B. Skotnicki;Tadeusz Robak;Branimir Jaksic

  • Guidelines for the diagnosis and management of adult aplastic anaemia.

    Sally B Killick;Nick Bown;Jamie Cavenagh;Inderjeet Dokal

  • Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;Petra Muus;Ulrich Dührsen;Antonio M. Risitano

Frequent Co-Authors

Andy C. Rawstron
Andy C. Rawstron Leeds Teaching Hospitals NHS Trust
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Susan O'Brien
Susan O'Brien University of California, Irvine
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
Steven Coutre
Steven Coutre Stanford University
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Anna Schuh
Anna Schuh University of Oxford
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Jennifer R. Brown
Jennifer R. Brown Harvard University
Tadeusz Robak
Tadeusz Robak Medical University of Lodz

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online health-related degrees is a flexible way to enter or advance in the medical field beyond traditional pathways. For those interested in pharmacy, understanding online pharmacy school cost can help you budget for further studies and make informed choices about your education investment.

If your interests align with healthcare administration and data, consider pursuing an online mhi (Master of Health Information Management) program. This option prepares you for critical roles in managing patient records and healthcare information systems.

For those seeking a quicker entry into the medical workforce, billing and coding classes online offer focused training for essential administrative positions, with courses ranging from a few months to a year.

Aspiring advanced clinicians may look into nurse practitioner programs, which can offer the convenience of online study while preparing for high-demand, patient-facing roles.

Best Scientists Citing Peter Hillmen

Trending Scientists

Recently Published Articles